|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Dr. Marc Hedrick, CEO of Plus Therapeutics, discusses the company’s targeted radiotherapeutic platform for central nervous system and solid tumor cancers and why internal radiation therapy offers patients a more advanced drug delivery solution compared to traditional external radiation therapy.
|
|
 |
|
When filing for a drug product approval via the 505(b)(2) regulatory pathway rather than a traditional development pathway, companies are afforded several advantages.
|
|
 |
|
Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….
|
|
|
|
|
|
|
|
|
Raza Bokhari, MD, Edward Brennan, MD, FACS, and Madison Weisz, MS, explore the D-MNA treatment, highlighting its drug delivery mechanisms, advantages over traditional treatments, and clinical potential.
|
|
|
James A. Roszell, PhD, and Doreen McMorran demonstrate how this technology has demonstrated potential in the transdermal administration of glucagon-like peptide-1 (GLP-1) agonists and cannabinoid receptor type 1 (CB-1) antagonists, primarily targeting obesity management and other conditions requiring glucose regulation.
|
|
|
Ronald Aung-Din, MD, Sasha Feygin, and Daniele La Rosa say Direct Effects topical perampanel is effective in treating headache and other neurological symptoms commonly encountered in patients with seizures and other conditions in which neuronal instability and hyper-excitability exist.
|
|
|
Zachary Rome, Jessica Raiz, MPH, and Alan M. Mendelsohn, MD, are advancing innovative clinical research that is evaluating high-potential, low-risk treatments for rare dermatologic diseases using unique topical vehicles combined with established medications that enable the targeted delivery of therapies to the epidermis and dermis while minimizing systemic absorption.
|
|
|
|
|
|
|
|
|

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics, small molecules, and RNA to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through the Celanese Development & Feasibility Lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization. Click here for more.
|
|
|
|
|
|
 |
|
In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.
|
|
 |
|
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
|
|
|
|
|
|
|
|
 |
|
Providing Ideal Protection for Invaluable Drug Products, Including Cell and Gene Therapy Products
Product Introduction of OXYCAPT™
OXYCAPT™ is a multilayer plastic vial and syringe, consisting of three layers made from two types of resins. The drug contact layer and …
|
|
 |
|
Our client, a leading pharmaceutical company, came to us for a solution to a very specific problem. They needed a staked needle prefilled syringe (PFS) in a disposable auto-injector for their high-concentration monoclonal antibody product. These products are among the …
|
|
 |
|
Veterinary medicines face unique challenges due to species diversity, physiology, and dosing needs. Animals can’t be instructed to take medicine, so palatability, safety, and bioavailability are key.
Gattefossé focuses on customers, veterinarians, pet owners, and animals themselves to help them …
|
|
|
|
|
Upcoming eNewsletter Features:
July 30 – Drug Delivery
August – 6 – Injection Devices
|
|
|
|
|
|
|
|